» Articles » PMID: 39659944

Effect of Subcutaneous Adipose Tissue-associated CSRP2 on the Progression of Prostate Cancer Via the WDR5/USP44 Pathway

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2024 Dec 11
PMID 39659944
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated subcutaneous adipose tissue in obese men correlates strongly with a higher risk of aggressive prostate cancer and poor treatment outcomes, but the exact mechanism underlying the increased risk remains elusive. To address this question, we analyzed prostate cancer transcriptomic data from The Cancer Genome Atlas as well as single-cell RNA sequencing and tissue microarray data from prostate cancer cells. Subcutaneous adipose tissue-associated cysteine-rich protein 2 (CSRP2) was significantly downregulated in prostate cancer epithelial cells. Knockdown of CSRP2 promoted proliferation of prostate cancer cell lines DU145 and PC3, whereas the opposite effect was observed with CSRP2 overexpression. xenograft assays confirmed that CSRP2 overexpression inhibits the growth of prostate cancer cells. Importantly, co-immunoprecipitation and mass spectrometry assays confirmed that CSRP2 inhibits the deubiquitination of WD40 repeat protein 5 (WDR5) by ubiquitin-specific protease 44 (USP44). Overexpression of WDR5 reversed the growth inhibition of CSRP2 overexpression on prostate cancer cells. Altogether, our data indicate that CSRP2 suppresses prostate cancer cell proliferation via a CSRP2/WDR5/USP44 dependent pathway to control prostate cancer progression, suggesting a potential mechanism for prostate cancer treatment.

References
1.
Boyd L, Mao X, Lu Y . The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012; 9(11):652-64. DOI: 10.1038/nrurol.2012.185. View

2.
Klimcakova E, Roussel B, Marquez-Quinones A, Kovacova Z, Kovacikova M, Combes M . Worsening of obesity and metabolic status yields similar molecular adaptations in human subcutaneous and visceral adipose tissue: decreased metabolism and increased immune response. J Clin Endocrinol Metab. 2010; 96(1):E73-82. DOI: 10.1210/jc.2010-1575. View

3.
Martinez-Jimenez F, Movasati A, Brunner S, Nguyen L, Priestley P, Cuppen E . Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature. 2023; 618(7964):333-341. PMC: 10247378. DOI: 10.1038/s41586-023-06054-z. View

4.
Schlick B, Massoner P, Lueking A, Charoentong P, Blattner M, Schaefer G . Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients. PLoS One. 2016; 11(2):e0147739. PMC: 4749310. DOI: 10.1371/journal.pone.0147739. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View